ANCN Anchiano Therapeutics Ltd
Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.
Company profile
Ticker
ANCN
Exchange
Website
CEO
Neil Cohen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BioCancell Ltd.
SEC CIK
Corporate docs
ANCN stock data
()
Calendar
16 Nov 20
21 Jan 21
31 Dec 21
News
Financial summary
| Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 12 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | |||
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 6.77M | 6.77M | 6.77M | |||
| Cash burn (monthly) | 685.33K | 818.67K | (positive/no burn) | |||
| Cash used (since last report) | 2.55M | 3.05M | n/a | |||
| Cash remaining | 4.22M | 3.72M | n/a | |||
| Runway (months of cash) | 6.2 | 4.5 | n/a | |||
Institutional ownership Q3 2020
1.8% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 7 |
| Opened positions | 2 |
| Closed positions | 1 |
| Increased positions | 0 |
| Reduced positions | 1 |
13F shares |
Current |
|---|---|
| Total value | 763K |
| Total shares | 670.61K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Palisade Capital Management | 369.64K | $421K |
| Meitav Dash Investments | 234.4K | $267K |
| PXGPE Phoenix | 26.09K | $28K |
| Regentatlantic Capital | 25K | $29K |
| VIRT Virtu Financial | 13.13K | $15K |
| Advisor | 2.35K | $3K |
| Proequities | 0 | $0 |
Financial report summary
?Competition
AMGEN • Spectrum Pharmaceuticals • Halo Technology • Halozyme Therapeutics • Altor Bioscience • Astellas Pharma • Taris Biomedical • Astellas Pharma • Aadi • Heat BiologicsManagement Discussion
- Our results of operations have varied in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period comparisons of our operating results are not necessarily meaningful and should not be relied upon as indications of future performance.
- Research and development expenses increased by approximately $5.8 million, 77%, to approximately $13.3 million for the year ended December 31, 2019 compared to approximately $7.5 million for the year ended December 31, 2018. The increase resulted primarily due to an increase in clinical trial expenses, manufacturing expenses and manpower expenses, as well as additional startup and initial ongoing expenses in connection with the Collaboration Agreement with ADT.
- General and administrative expenses increased by approximately $0.7 million, 13%, to approximately $6.2 million for the year ended December 31, 2019 compared to approximately $5.5 million for the year ended December 31, 2018. The increase was primarily due to increases in professional fees, insurance and manpower expenses, offset by a decrease in share-based payment.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
Financial reports
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
17 Mar 20
20-F/A
2018 FY
Annual report (foreign) (amended)
24 Apr 19
20-F
2018 FY
Annual report (foreign)
25 Mar 19
20-F
2012 FY
Annual report (foreign)
23 Apr 13
Current reports
8-K
Anchiano Therapeutics and Chemomab Announce Entry Into
15 Dec 20
8-K
Departure of Directors or Certain Officers
20 Oct 20
8-K
Departure of Directors or Certain Officers
15 Jul 20
8-K
Departure of Directors or Certain Officers
9 Jul 20
8-K
Departure of Directors or Certain Officers
21 May 20
8-K
Anchiano Appoints Steve DiPalma as Chief Financial Officer
6 May 20
8-K
Submission of Matters to a Vote of Security Holders
24 Apr 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Apr 20
8-K
Other Events
16 Mar 20
8-K
Departure of Directors or Certain Officers
10 Feb 20
Registration and prospectus
S-4
Registration of securities issued in business combination transactions
13 Jan 21
425
Business combination disclosure
11 Jan 21
425
Business combination disclosure
5 Jan 21
S-8
Registration of securities for employees
17 Mar 20
S-8
Registration of securities for employees
22 Jul 19
424B4
Prospectus supplement with pricing info
13 Feb 19
F-1/A
Registration statement (foreign) (amended)
11 Feb 19
8-A12B
Registration of securities on exchange
8 Feb 19
F-1/A
Registration statement (foreign) (amended)
8 Feb 19
F-1/A
Registration statement (foreign) (amended)
5 Feb 19
Ownership
SC 13D/A
Anchiano Therapeutics / Access Industries ownership change
21 Dec 20
SC 13D/A
Anchiano Therapeutics / Palisade Medical Equity I ownership change
18 Dec 20
SC 13D/A
Anchiano Therapeutics / Palisade Medical Equity I ownership change
22 May 20
3
Anchiano Therapeutics / Stephen J. DiPalma ownership change
7 May 20
SC 13D/A
Anchiano Therapeutics / Access Industries ownership change
31 Mar 20
SC 13D/A
Anchiano Therapeutics Ltd.
13 Jan 20
3
Anchiano Therapeutics / Ofer Gonen ownership change
2 Jan 20
3
Anchiano Therapeutics / Len Blavatnik ownership change
2 Jan 20
3
Anchiano Therapeutics / REGINALD L HARDY ownership change
2 Jan 20
3
Anchiano Therapeutics / Ruth Alon ownership change
2 Jan 20